# Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

> **NCT03556358** · PHASE3 · COMPLETED · sponsor: **Tanvex BioPharma USA, Inc.** · enrollment: 809 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- HER2-positive Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer

## Interventions

- **BIOLOGICAL:** TX05 (trastuzumab)
- **BIOLOGICAL:** Herceptin®
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03556358
- **Lead sponsor:** Tanvex BioPharma USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-28
- **Primary completion:** 2020-11-27
- **Final completion:** 2021-02-04
- **Target enrollment:** 809 (ACTUAL)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556358, "Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03556358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*